{
  "docId": "019de076-b194-750c-a1e9-eae1d42bc6f5",
  "docSlug": "9fdf48e9810bc95033985664c53d0e5a",
  "documentTitle": "Mainz Biomed NV | Investor Presentation Deck | 24 slides",
  "authorId": "mainz-biomed-nv",
  "authorName": "Mainz Biomed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 24,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "The table compares two distinct clinical trials (ColoFuture and eAArly DETECT) across key performance metrics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b194-750c-a1e9-eae1d42bc6f5/14",
  "deckHref": "/decks/019de076-b194-750c-a1e9-eae1d42bc6f5",
  "deckJsonHref": "/decks/019de076-b194-750c-a1e9-eae1d42bc6f5.json",
  "deckAnchorHref": "/decks/019de076-b194-750c-a1e9-eae1d42bc6f5#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.53,
        "x": 0.043,
        "y": 0.158
      },
      "kind": "list",
      "text": "Mainz Biomed has recently completed two successful clinical trials for CRC screening. Combined, the trials collected data from 474 participants across 28 sites. ColoFuture (EU) and eAArly DETECT (US) both assessed the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert, the company’s efficacious CRC screening test on the market in Europe. The mRNA biomarkers in combination with the FIT test enabled high CRC sensitivity & specificity but also remarkably high advanced adenoma (AA) sensitivity. The industry-leading performance has the potential to enable the transition from CRC early cancer screening to CRC prevention with AA screening.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ac6b7bd-44f4-4e6b-8567-bce99ca2e5b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.26,
        "x": 0.038,
        "y": 0.885
      },
      "kind": "source-note",
      "text": "Source: Company websites and press releases.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fd3fe0f-f942-4783-977a-6bf1ab2a0756",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.478,
        "w": 0.378,
        "x": 0.566,
        "y": 0.237
      },
      "kind": "table",
      "text": "Mainz Biomed ColoFuture eAArly DETECT CRC Sensitivity 94% 97% CRC Specificity 97% 97% AA Sensitivity 80% 82% AA Specificity 95% 97% Location EU US # of Participants 220 254 # of Study Sites 7 21",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd8b23fa-15c0-43ef-bf67-fa3fc095773a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.805,
        "x": 0.048,
        "y": 0.035
      },
      "kind": "title",
      "text": "Highly Promising Colorectal Cancer (CRC) Clinical Trial Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bebb09a7-4d76-4ecd-bba7-3cd2242fa37f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}